| Document |
Document Title |
|
WO/1999/032430A1 |
The present invention relates to a novel process for the synthesis of isopropyl-methyl-[2-(3-n-propoxyphenoxy)ethyl]amine. Moreover, the present invention also relates to a novel intermediate and an optional purification step in the nove...
|
|
WO/1999/026614A1 |
This invention is related to substituted 2-aminoacetamides represented by formula (II): or a pharmaceutically acceptable salt or prodrug thereof, wherein the substituents are defined herein. The invention also is directed to the use of s...
|
|
WO/1999/025349A1 |
A pharmaceutically acceptable aqueous solution which is isobaric or hyperbaric, and isotonic, with respect to cerebrospinal fluid (CSF), comprises a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide anaesthetic agent such as bupivac...
|
|
WO/1999/022717A1 |
The present invention is directed to a novel topical pharmaceutical water-in-oil composition in form of a cream or lotion, comprising i) 2-50 % of a local anaesthetic in oil form in the final composition, or two or more local anaesthetic...
|
|
WO1999008729A9 |
A medical device, polymer composition, and method for delivering substantially water-insoluble drugs to tissue at desired locations within the body. At least a portion of the exterior surface of the medical device is provided with a poly...
|
|
WO/1999/013865A1 |
The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release $i(in vivo). When the encapsulated anesthetic is administere...
|
|
WO/1999/012521A1 |
The invention provides a pharmaceutical composition for rectal ou vaginal administration which comprises at least two parts wherein the composition comprises (i) two or more physiologically acceptable substances each in separate parts of...
|
|
WO/1999/012523A1 |
Disclosed is a method for making liposomes, for example multivesicular liposomes (MVLs), containing one or more biologically active agents, wherein the loading of the active agents into the liposomes is modulated by adjusting the osmolar...
|
|
WO/1999/004772A2 |
A method of anaesthetising a human patient prior to major surgery, which comprises the administration to the patient of at least 200 mg levobupivacaine.
|
|
WO/1999/004771A2 |
Levobupivacaine is particularly suitable for use in anaesthetising a human patient prior to surgery that does not require hospitalisation for more than 12 hours after loss of motor block. Because of its beneficial motor block/sensory blo...
|
|
WO/1999/003473A1 |
Compositions, methods and kits for inhibiting a cerebral neurovascular disorder or a muscular headache in a human patient are disclosed. Also disclosed are uses of a long-acting local anesthetic ingredient for manufacturing a medicament ...
|
|
WO/1999/002252A1 |
In the formation of capsules having a polyanionic polysaccharide core and a polycationic polysaccharide membrane layer, improved binding of the polycationic polysaccharide is achieved by including polyvalent ions, especially calcium ions...
|
|
WO/1999/001114A1 |
Sustained release local anesthetic formulations are administered intra articularly and/or into body spaces/cavities. The formulation is preferably a plurality of injectable microparticles including a local anesthetic and an effective amo...
|
|
WO/1998/057643A1 |
This invention concerns the use of nucleoside transport inhibitors, more particularly compounds of formula (I), an $i(N)-oxide form, a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof, wherein R?...
|
|
WO/1998/053805A1 |
Aqueous, injectable pharmaceutical formulation comprising propofol, a pharmaceutically acceptable salt of a bile acid and a lecithin.
|
|
WO/1998/047869A1 |
This invention is related to carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones represented by formula (I), or a pharmaceutically acceptable salt or prodrug thereof, wherein: Y is oxygen or sulfur; R�1?, Rï¿...
|
|
WO/1998/046235A1 |
The invention relates to orally applicable pharmaceutical preparations containing a fixed combination of at least one locally quick acting analgesic and at least one systematically long-acting analgesic.
|
|
WO/1998/042674A1 |
Ultrashort acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein: X is halogen; h is f...
|
|
WO/1998/042675A1 |
Ultra short acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein q and t are independ...
|
|
WO/1998/040084A1 |
A device for inducing anaesthesia, analgesia and/or sedation is described which comprises a container holding an inert gas-containing liquid preparation, and means for the controlled administration of the preparation to a patient.
|
|
WO/1998/040083A1 |
A preparation is described which contains a lipophilic gas with a pharmacological action in dissolved or dispersed form. This preparation is particularly suitable for inducing anaesthesia.
|
|
WO/1998/040070A1 |
Methods and compositions for treating pain at a specific site with an effective concentration of capsaicin or analogues thereof are described. The methods involve providing anesthesia to the site where the capsaicin or analogues thereof ...
|
|
WO/1998/038999A1 |
Levobupivacaine is used for providing anaesthesia or analgesia in human paediatric surgery.
|
|
WO/1998/038854A1 |
Disclosed is a pharmaceutical composition intended for the topical application to human skin, comprising (A) as an effective ingredient, a mixture comprising (1) an antibiotic medication, (2) an antihistamine; and (B) a physiologically a...
|
|
WO/1998/038996A1 |
Levobupivacaine is used for providing anaesthesia or analgesia in a human patient in and after facial surgery, especially dentistry or ophthalmics.
|
|
WO/1998/038165A1 |
The 5HT�2? receptor antagonizing effect of 2'-[2-(1-methyl-2-piperidyl) ethyl] cinnamanilide, a racemic mixture (R S-MPEC) of S-MPEC and R-MPEC isomers is found to be provided practically entirely by the S-MPEC isomer, the R-MPEC being...
|
|
WO/1998/036777A1 |
Compounds and methods which are useful for the site-specific delivery and localization of drugs are provided. The compounds can be represented by the formula: A-L-D wherein A is an anchoring moiety; L is a linking group; and D is a drug.
|
|
WO/1998/032430A1 |
The present invention relates to an anesthetic composition containing an anhydrous fluoroether compound and a physiologically acceptable Lewis acid inhibitor (e.g. water, butylated hydroxygene, methylparaben, propofol, thymol). This comp...
|
|
WO/1998/020852A1 |
The present invention provides pharmaceutical compositions comprising an effective amount of dermopharmaceutical active agent, kukui nut oil and a pharmaceutically acceptable base which comprises ingredients selected from the group consi...
|
|
WO/1998/020869A2 |
The invention relates to formulations for the electrically assisted transdermal delivery of lidocaine and epinephrine. The present invention further provides methods and devices for the electrically assisted delivery of local anesthetics...
|
|
WO/1998/017285A1 |
Pharmaceutical preparations are described, comprised of salts of hyaluronic acid with a basic anaesthetic containing aliphatics and/or amino groups, particularly salts with benzydamine or bupivacaine.
|
|
WO/1998/016212A1 |
A local anesthetic for external use is prepared by blending a) an active ingredient selected from lidocaine, prilocaine, and pharmaceutically acceptable salts thereof, b) a percutaneous absorption accelerator, c) ethanol and/or isopropyl...
|
|
WO/1998/012177A1 |
A compound of formula (I) and the salts thereof, wherein A is halo, hydroxy or the like; the broken line represents an optional double bond with proviso that if the broken line is a double bond, then A is absent; Ar?1� is optionally su...
|
|
WO/1998/010746A1 |
The present invention generally relates to pharmaceutical compositions that enable control of drug delivery properties and the development of optimal drug delivery strategies customized for particular drugs and particular diseases. The c...
|
|
WO/1998/010769A1 |
The use of glucocorticosteroids in methods and formulations for prolonging and/or reactivating local anesthesia or local anesthesia previously induced by a local anesthetic agent, is disclosed.
|
|
WO/1998/003163A1 |
The present invention provides compositions comprising licodaine and emu oil. The compositions are useful in a method of anesthetizing cornified skin comprising topically administering the subject compositions. The present compositions a...
|
|
WO/1998/000173A2 |
The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the $i(in-vivo) release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may ...
|
|
WO/1997/049391A1 |
Methods and formulations for inducing substantially safer local anesthesia in a patient are provided. The methods comprise administering, to a patient in need thereof, a substrate containing a local anesthetic and an effective amount of ...
|
|
WO/1997/042952A1 |
A percutaneous tape preparation containing fentanyl or its salt, a pressure-sensitive adhesive and sodium acetate. It is preferable that the salt of fentanyl is fentanyl citrate. This preparation is little irritative to the skin and exce...
|
|
WO/1997/038675A1 |
The invention is directed to a novel pharmaceutical composition comprising one or more local anaesthetics in oil form, one or more surfactants, water and optionally a taste masking agent. The novel composition is advantageously used as a...
|
|
WO/1997/038663A2 |
A buccal aerosol spray or capsule using a non-polar solvent has now been developed which provides biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal aerosol spray of ...
|
|
WO/1997/035585A1 |
The present invention provides a method for providing anesthesia using a composition comprising olanzapine and one or more opioids.
|
|
WO/1997/034588A1 |
Formulations of phospholipid-coated microdroplets of propofol devoid of fats and triglycerides provide chronic sedation over extended periods of time without fat overload. Being free of nutrients that support bacterial growth, these micr...
|
|
WO/1997/024354A1 |
The disclosure relates to substituted 6-R-1,3,4-thiadiazine-2-amines of general formula (I), in which Ar stands for phenyl which may be substituted with one or more atoms of chlorine, bromine, C1-C4 alkoxy or C1-C4 alkyl groups; R1 and R...
|
|
WO/1997/024353A1 |
The disclosure relates to substituted 6-H-1,3,4-thiadiazine-2-imines of general formula (I), in which (II) represents a morpholine, thiomorpholine, piperidine, pyrrolidine or hexamethylene imine fragment, or to the pharmacologically acce...
|
|
WO/1997/016440A1 |
This invention concerns the compounds of formula (I), the N-oxide forms, the pharmaceutically acceptable addition salts and the stereoisomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is...
|
|
WO/1997/015548A1 |
There is provided compounds of formula (I), wherein R1 represents C3-5 alkyl; and R2 and R3 independently represent C1-3 alkyl; provided that when R2 and R3 both represent ethyl, then R1 does not represent n-butyl, i-butyl or n-pentyl; o...
|
|
WO/1997/007750A1 |
The present invention relates to the management of pain without requiring or allowing for reduction in the level of administration of narcotics, and to self-management of pain on an outpatient basis. Accordingly, the present invention is...
|
|
WO/1997/007793A1 |
The present invention pertains to the field of pain management in medicine. Methods for treating reflex sympathetic dystrophy (including causalgia) are provided, in which a haloalkylamine 'alpha' adrenergic blocking agent and a local ana...
|
|
WO/1997/004728A1 |
An apparatus, product formulation, and method for improved dermal permeation of pharmaceuticals wherein the apparatus includes a thin drug formulation reservoir and a heat-generating chamber separated by a first non-permeable wall, where...
|
